The Journal of Psychoactive Drugs is a peer-reviewed medical journal on psychoactive drugs. It was established in 1967 by David E. Smith and is currently published five times per year by Taylor & Francis. It was previously titled Journal of Psychedelic Drugs until 1980.[1][2] It was the first journal established in the United States to focus on psychoactive drug use, and continues to introduce groundbreaking work in topics such as drug use and criminality, therapeutic communities, dual diagnosis, psychotherapy/counseling, methadone maintenance treatment, and culturally-relevant substance abuse treatment. According to the Journal Citation Reports, the journal has a 2016 impact factor of 1.740.[3]
| Discipline | Pharmacology |
|---|---|
| Language | English |
| Publication details | |
Former name(s) | Journal of Psychedelic Drugs |
| History | 1967–present |
| Publisher | |
| 2.80 (2022) | |
| Standard abbreviations | |
| ISO 4 | J. Psychoact. Drugs |
| Indexing | |
| ISSN | 0279-1072 (print) 2159-9777 (web) |
| Links | |
References
edit- ^ "Erowid Periodical Library: The Journal of Psychedelic Drugs". Erowid.org. Retrieved 2008-10-07.
- ^ "Journal of Psychoactive Drugs information". www.tandfonline.com. Retrieved 2022-02-24.
- ^ "Journal of Psychoactive Drugs". 2012 Journal Citation Reports. Web of Science (Science ed.). Thomson Reuters. 2013.
External links
edit
 | This hallucinogen-related article is a stub. You can help Wikipedia by expanding it. |
  | This article about a psychiatry journal is a stub. You can help Wikipedia by expanding it. See tips for writing articles about academic journals. Further suggestions might be found on the article's talk page. |